Strategies to Advance m Ab Production

摘要

While approval of new therapeutic antibodies has not progressed as rapidly as was forecast 10 years ago, new products are moving through the pipeline. As always, bioprocessing, critical to antibody manufacture, is a key factor in the cost and efficiency of production. Interviews with company officials and researchers engaged in bioprocessing showed how novel approaches to these challenges are moving the industry forward. All of the experts GEN spoke to will discuss new scientific developments and recent technological advances at BIT's "International Congress of Antibodies" meeting in Beijing later this month.